Compare HBB & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HBB | STRO |
|---|---|---|
| Founded | 1904 | 2003 |
| Country | United States | United States |
| Employees | N/A | 131 |
| Industry | Home Furnishings | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 252.9M | 338.9M |
| IPO Year | 2017 | N/A |
| Metric | HBB | STRO |
|---|---|---|
| Price | $18.41 | $39.16 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $31.33 |
| AVG Volume (30 Days) | 14.2K | ★ 211.2K |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.38% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | ★ $606,852,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $71.75 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.72 | $0.67 |
| 52 Week High | $21.84 | $41.88 |
| Indicator | HBB | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 39.89 | 64.55 |
| Support Level | $17.95 | $10.50 |
| Resistance Level | $20.79 | N/A |
| Average True Range (ATR) | 1.40 | 3.42 |
| MACD | -0.37 | -0.20 |
| Stochastic Oscillator | 11.52 | 63.89 |
Hamilton Beach Brands Holding Co, through its subsidiaries, is engaged in consumer, commercial, and specialty small appliances and specialty retail. It designs, markets, and distributes small branded electric household and specialty housewares small appliances, as well as commercial products for restaurants, bars, and hotels. It has two operating segments Home and Commercial Products segment includes consumer product revenue consisting of sales of small electric household and specialty housewares appliances whereas the health segment includes lease revenue associated with leases of connected devices to specialty pharmacy networks and pharmaceutical companies, as well as licensing revenue which grant customers the right to use software for healthcare management.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.